Showing results (31-40 of 78) with videos related to
Sort By:
Pageof 8
Expert Opinion on Pharmacotherapy|September 14, 2020
Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendationsAmanda Mogul, Emily E Leppien, Elizabeth Laughlin, et al.The Annals of Pharmacotherapy|May 22, 2009
Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settingsEdith A Nutescu, Sarah A Spinler, Ann Wittkowsky, et al.Journal of the American Pharmacists Association : Japha|November 25, 2003
Plasma cholesterol concentrations, dietary fat intake, and cholesterol intake in pharmacy studentsSarah A Spinler, Simon de Denus, Grace Earl, et al.Pharmacotherapy|May 28, 2004
Statins and liver toxicity: a meta-analysisSimon de Denus, Sarah A Spinler, Kristin Miller, et al.Pharmacotherapy|December 31, 2004
Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation managementEdith A Nutescu, Sarah A Spinler, William E Dager, et al.The Annals of Pharmacotherapy|June 16, 2005
Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparinSarah A Spinler, Ann K Wittkowsky, Edith A Nutescu, et al.Pharmacotherapy|October 23, 2002
Combination antiplatelet therapy: implications for pharmacistsRobert L Talbert, Sarah A Spinler, Jean M Nappi, et al.Journal of the American Pharmacists Association : Japha|April 21, 2004
Antithrombotic therapy for acute coronary syndromesSarah A Spinler, Stephanie M Inverso, Janet H Dailey, et al.The Annals of Pharmacotherapy|April 28, 2005
Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitorsSarah A Spinler, Edith A Nutescu, Maureen A Smythe, et al.The Annals of Pharmacotherapy|June 16, 2020
Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney DiseaseJudy W M Cheng, Vincent Colucci, James S Kalus, et al.Pageof 8